Search Results
Dec 18, 2025, 09:00 ET Delayed Gift? DoorDash Saves the Day with its Holiday Gift Rescue
DoorDash's sweepstakes posts if you could use some holiday rescuing.This comment will trigger participation in the sweepstakes, and an auto DM will be sent from DoorDash with a link to the entry form.Complete the entry form with details including the delayed gift item, value of item,
More news about: DoorDash
Dec 17, 2025, 16:38 ET Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes
randomized, double-blind, placebo-controlled clinical study evaluating balomenib, a novel oral menin inhibitor, in adults with type 2 diabetes mellitus (T2DM). The study received formal regulatory authorization in September and is expected to enroll up to 60 participants."This milestone marks
More news about: Clywedog Therapeutics, Inc.
Dec 17, 2025, 11:00 ET Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes
APAC.F. Hoffmann-La Roche Ltd.Key Breast Cancer Products: Herceptin (trastuzumab), Perjeta (pertuzumab), Kadcyla (T-DM1), Phesgo (SC pertuzumab/trastuzumab), Tecentriq (atezolizumab)Core strengths: Global benchmark in HER2-targeted therapy
More news about: DataM Intelligence 4 Market Research LLP
Dec 16, 2025, 09:03 ET Founders Row Announces First Portfolio Investment, Backing Hot Box Pretzels
as one of the most exciting emerging snack brands breaking into the national spotlight, now with financial backing.Two years after that cold DM, what began as a simple message has grown into Founders Row's first official investment and a true partnership between Desmond and Jamie Weeks.
More news about: Founders Row
Dec 15, 2025, 04:00 ET 歌禮宣佈有望成為同類最佳口服小分子IL-17抑制劑ASC50美國I期研究取得積極的頂線結果
-167，或如下的鏈接參與直播：中國內地：https://meeting.tencent.com/dm/eb7KovQX2hYD；或國際：
More news about: 歌禮製藥有限公司
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
https://meeting.tencent.com/dm/eb7KovQX2hYD; orInternational: https://voovmeeting.com/dm/eb7KovQX2hYD.About Ascletis Pharma Inc.Ascletis
More news about: Ascletis Pharma Inc.
Dec 12, 2025, 09:42 ET JETOUR Kicks Off "Middle East Hybrid Night" in Oman, Debuts Three New Models Led by G700
BIDIYAH, Oman, Dec. 12, 2025 /PRNewswire/ -- JETOUR launched three hybrid models—the G700, T2 i-DM, and T1 i-DM—during the vibrant Bidiyah Festival, one of Oman's most iconic outdoor and motorsport events.
More news about: Jetour
Dec 11, 2025, 10:00 ET JAECOO 7 SHS eleva el estándar de las SUV súper híbridas al superar a sus competidoras clave en desempeño, autonomía y eficiencia
ventajas claras para el modelo. De acuerdo con los análisis comparativos, JAECOO 7 SHS alcanza una autonomía total superior a la de BYD Song Plus DM-i, asegurando recorridos más amplios y reduciendo la necesidad de detenerse a recargar o repostar gasolina. En modo completamente eléctrico, la SUV supera
More news about: JAECOO
Dec 11, 2025, 08:30 ET WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS
hemolyzed blood samples in the emergency department. J Appl Lab Med.2021;6(6):1607–1610. doi:10.1093/jalm/jfab035Phelan MP, Hustey FM, Good DM, Reineks EZ. Seeing red: blood sample hemolysis is associated with prolonged emergency department throughput. J Appl Lab Med. 2020;5(4):732–737.
More news about: Werfen
Dec 02, 2025, 08:03 ET Diebold Nixdorf Unveils DN Series® 300 and 350: Transforming Self-Service Banking
New cash dispensers, powered by the new DM7V dispensing module, combine the industry's highest capacity with the smallest footprint, reducing operational cost.NORTH CANTON, Ohio, Dec. 2, 2025 /PRNewswire/ -- Diebold
More news about: Diebold Nixdorf, Incorporated
Nov 30, 2025, 05:15 ET 歌禮選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
接參與直播：中國內地：https://meeting.tencent.com/dm/10ve6whW8Rbl；或國際：https://voovmeeting.com/dm/10ve6whW8Rbl。關於歌
More news about: 歌禮製藥有限公司
Nov 30, 2025, 05:15 ET Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
https://meeting.tencent.com/dm/10ve6whW8Rbl; orInternational: https://voovmeeting.com/dm/10ve6whW8Rbl.About Ascletis Pharma Inc.Ascletis
More news about: Ascletis Pharma Inc.
Nov 20, 2025, 09:00 ET Mucinex® Introduces New Clear & Cool Sinus Nasal Spray, Delivering Instant Cooling Relief for Congestion
12-hour products that work to thin and loosen excess mucus, relieve chest congestion, and control coughing. The Mucinex 12-Hour line, including Mucinex DM for cough and chest congestion and Mucinex SE for chest congestion, provides powerful, long lasting relief day or night. Mucinex
More news about: Mucinex
Nov 19, 2025, 09:13 ET Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.
Nov 13, 2025, 09:08 ET TheraBreath™ and Jake Shane Offer Fans the Chance to Freshen Up with a Session of "Breathapy"
to freshen up and a promotional code to claim a TheraBreath toothpaste sample. Those interested in making a nomination can send a direct message (DM) to @TheraBreath on
More news about: TheraBreath
Nov 13, 2025, 07:18 ET Dealism se asegura $ 15 millones en fondos ángel para interrumpir la participación del cliente en Brasil
complejas que ayudan activamente a vender y cerrar tratos. La plataforma admite múltiples canales de comunicación, incluidos WhatsApp Web, Instagram DM y una aplicación dedicada, lo que permite a las empresas mantener un compromiso profesional y oportuno con sus clientes.
More news about: DEALISM PTE. LTD.
Nov 12, 2025, 18:30 ET 歌禮宣布每月一次新一代胰澱素受體激動劑ASC36和每月一次新一代GLP-1R/GIPR雙靶點激動劑ASC35的復方制劑進入臨床開發階段
中國內地：https://meeting.tencent.com/dm/uIyhG5Mtu3op；或 國際：https://voovmeeting.com/dm/uIyhG5Mtu3op。
More news about: 歌禮製藥有限公司
Nov 12, 2025, 18:30 ET Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
https://meeting.tencent.com/dm/uIyhG5Mtu3op; or International: https://voovmeeting.com/dm/uIyhG5Mtu3op. About
More news about: Ascletis Pharma Inc.
Nov 12, 2025, 14:30 ET UT Health San Antonio Center for Brain Health celebrates 'a new era of hope, healing and discovery' with ribbon-cutting
Sudha Seshadri, MD, DM, neurology professor and founding director of the Biggs Institute. "It is deeply meaningful to me, both personally and professionally, to offer
More news about: UT Health San Antonio
Nov 10, 2025, 16:05 ET Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
treatment of myotonic dystrophy type 1 (DM1): In July 2025, Avidity announced completion of enrollment for the Phase 3 HARBOR™ trial, the first global Ph3 trial of del-desiran for the treatment of DM1. Expected
More news about: Avidity Biosciences, Inc.
Nov 10, 2025, 15:03 ET dmTECH modernizes customer engagement with SAS Customer Intelligence 360 and Snowflake
internationally as babybonus), dm offers parents a wide range of benefits – from pregnancy through their child's 12th birthday. These include parenting tips, giveaways, app-based coupons, product testing opportunities, and more. One of the key challenges for dm was accurately assigning customers
More news about: SAS
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, vanoglipel was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
More news about: MetaVia Inc.
Nov 06, 2025, 06:45 ET Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
study intervention (with possible dose interruptions and/or dose modifications) for 48 weeks. Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats
More news about: Eli Lilly and Company
Nov 06, 2025, 01:00 ET JIN-ASAKUSA Debuts New Course: Sushi x Samurai x Entertainment Experience
international tourists.Official Instagram: https://www.instagram.com/p/DM2ZsHAx1Jk/ Immersive ExperienceThe restaurant offers a hands-on experience in an extraordinary interior designed
More news about: Prex Co., Ltd.
Nov 05, 2025, 10:57 ET Late-Breaking Clinical Trial Results Announced at VIVA 2025
(59%) had DM and 55 (41%) did not. At 36 months, Kaplan–Meier estimates showed freedom from TLR of 93.5% in the DM group and 94.3% in the non-DM group. Primary patency was 83.0% in DM patients vs 79.3% in non-DM patients. All-cause mortality was 2.8% in the DM group and 5.9% in the non-DM group.
More news about: The VIVA Foundation